The history of GC Biopharma is defined

by consistent dedication and continuous innovation.

Driven by our commitment
to meeting patients’ needs,

we persist in developing cutting-edge solutions
that contribute to a healthier future.

2010 ~ Present

  • 2023

    • Obtained U.S. FDA approval for the blood product [ALYGLO]
    • Obtained WHO PQ certification for the Ochang W&FF (Warehouse & Fill and Finish) Facility
    • Reached a milestone of producing 300 million doses of flu vaccines
    • Obtained WHO PQ certification for the varicella vaccine Varicella
    • Established a company-wide compliance management system

  • 2021

    • Obtained Japanese approval for [Hunterase ICV], the world’s first intraventricular treatment for severe Hunter syndrome, and Chinese approval for [GreenGene F]

  • 2020

    • Obtained approval in China for [Hunterase], the country’s first treatment for Hunter syndrome
    • Obtained approval for the next-generation varicella vaccine [Varicella]

  • 2019

    • Reached a production milestone of 200 million doses of flu vaccines

  • 2018

    • Won the $200 Million Export Tower Award

  • 2016

    • Received approval for Korea’s first tetanus-diphtheria vaccine [GC-Td Vaccine]
    • Secured WHO PQ approval for the quadrivalent flu vaccine [GC Flu Quadrivalent]

  • 2015

    • Gained approval for Korea’s first avian influenza vaccine [GC Flu H5N1]
    • Obtained approval for the world’s fourth quadrivalent flu vaccine [GC Flu Quadrivalent]

  • 2014

    • Won the $100 Million Export Tower Award and received the Gold Tower Order of Industrial Service Merit
    • Reached a milestone of producing 300 million doses of flu vaccines

  • 2013

    • Completed construction of the GC R&D Center, the largest research facility in Korea's pharmaceutical industry
    • Held the groundbreaking ceremony for a blood product plant at the Thai Red Cross

  • 2012

    • Obtained approval for the world’s second Hunter syndrome treatment [Hunterase]

  • 2011

    • Gained approval for the osteoarthritis treatment [Shinbaro], a natural herbal medicine

2000 ~ 2010

  • 2009

    • Completed the construction of the Ochang Plant, a state-of-the-art facility for plasma-derived and recombinant protein products
    • Received approval for [GreenFlu], the swine flu vaccine, and [GC Flu], Korea's first flu vaccine
    • Completed the construction of Korea’s first vaccine-dedicated plant in Hwasun

  • 2008

    • Obtained approval for [GreenGene], the world’s fourth recombinant hemophilia A treatment

  • 2001

    • Acquired Sang-A Pharmaceutical

  • 2000

    • Established a Urokinase plant in North Korea

1990 ~ 1999

  • 1995

    • Established a vaccine plant in Indonesia
    • Established GC China

  • 1993

    • Obtained approval for [Varivax], the world’s second chickenpox vaccine

  • 1990

    • Founded the Korea Hemophilia Foundation

1980 ~ 1989

  • 1989

    • GC Biopharma completed its Initial Public Offering (IPO)

  • 1988

    • Received approval for [Hantavax], the world’s first hemorrhagic fever with renal syndrome (HFRS) vaccine

  • 1983

    • Obtained approval for [Hepavax-B], the world’s third hepatitis B vaccine

  • 1982

    • Obtained approval for the intravenous immunoglobulin therapy [IV-Globulin]

1967 ~ 1979

  • 1974

    • Obtained approval for the antihemophilic factor [AHF]

  • 1973

    • Obtained approval for Korea’s first stroke treatment, [Urokinase]

  • 1971

    • Began producing Korea's first blood products
    • Changed the company’s name to GC Biopharma

  • 1968

    • Constructed the Shingal Plant

  • 1967

    • Established Suh-Doo Microbial Pharmaceutical Co., Ltd.

The Legacy Behind
GC Biopharma’s Success

GC Biopharma’s accomplishments today are the result of decades of dedication and perseverance.
For over fifty years, our people’s passion and commitment have propelled us forward.
Whether in research, sales, or production, it is the collective effort of every individual that has earned us the global trust we hold today.